Sectors
STTK
Shattuck Labs, Inc.
7.08
1 x 6.27
1 x 7.92
bid
ask
-
0.05
0.77%
09:36 AM
timesize
| Ytd | 94.11% | |
| 1y | 837.17% |
7.05
day range
7.18
0.71
52 week range
8.33
| Open | 7.18 | Prev Close | 7.14 | Low | 7.05 | High | 7.18 | Mkt Cap | 340.11M |
| Vol | 24.22K | Avg Vol | 1.29M | EPS | -0.63 | P/E | -11.27 | Forward P/E | -1.03 |
| Beta | 1.08 | Short Ratio | 1.76 | Inst. Own | 74.67% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 6.21 | 200-d Avg | 4.97 | 1yr Est | 1.20 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.41 | -0.33 | 0.08 | 19.51% |
| 2024-08-01 | 2024-06 | -0.41 | -0.42 | -0.01 | -2.44% |
| 2024-08-01 | 2024-06 | -0.41 | N/A | N/A | N/A |
| 2024-05-02 | 2024-03 | -0.47 | -0.37 | 0.1 | 21.28% |
| 2024-05-02 | 2024-03 | -0.47 | N/A | N/A | N/A |
| 2024-02-29 | 2023-12 | -0.51 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-11-14 | Needham | Upgrade | Hold | |
| 2024-10-02 | Citigroup | Downgrade | Buy | Neutral |
| 2024-10-02 | Needham | Downgrade | Buy | Hold |
| 2024-10-01 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2024-08-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-27 | BROUS TYLER | Director | 238.09K | Purchase |
| 2024-01-09 | DEYOUNG CASI | Officer | 91.50K | Stock Award(Grant) |
| 2024-01-09 | NEILL ANDREW R. | Chief Financial Officer | 173.45K | Stock Award(Grant) |
| 2024-01-09 | PANDITE ARUNDATHY N. | Officer | 219.28K | Stock Award(Grant) |
| 2024-12-03 | REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-10-06 | SCHREIBER TAYLOR M.D., PH.D. | Chief Executive Officer | 2.68M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 7.16M | 7.87M | 15.00% |
| 2024-09-29 | Prosight Management, Lp | 5.68M | 6.25M | 11.90% |
| 2024-09-29 | Redmile Group, LLC | 5.62M | 6.18M | 11.76% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 2.90M | 3.19M | 6.07% |
| 2024-09-29 | Blackrock Inc. | 2.61M | 2.87M | 5.47% |
| 2024-09-29 | Vanguard Group Inc | 2.40M | 2.64M | 5.03% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.31M | 1.45M | 2.75% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.02M | 1.12M | 2.14% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 692.87K | 762.16K | 1.45% |
| 2024-08-30 | Fidelity Series Small Cap Opportunities Fund | 622.74K | 685.01K | 1.30% |
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 505.80K | 556.38K | 1.06% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 401.78K | 441.95K | 0.84% |